Astrana Health, Inc. (NASDAQ:ASTH) Given Average Recommendation of “Buy” by Analysts

Astrana Health, Inc. (NASDAQ:ASTH) has received a consensus rating of “Buy” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $62.00.

Several analysts recently weighed in on the company. BTIG Research raised their price objective on Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, October 3rd. TD Cowen began coverage on Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 price target on the stock. Robert W. Baird lifted their price target on Astrana Health from $54.00 to $67.00 and gave the company an “outperform” rating in a research note on Thursday, August 15th. Stifel Nicolaus lifted their price target on Astrana Health from $48.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, Truist Financial lifted their price target on Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, August 9th.

Astrana Health Stock Performance

NASDAQ:ASTH opened at $55.68 on Monday. The stock’s 50-day simple moving average is $54.09 and its 200 day simple moving average is $46.42. The firm has a market capitalization of $3.12 billion, a PE ratio of 42.18, a price-to-earnings-growth ratio of 2.20 and a beta of 1.21. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.62. Astrana Health has a twelve month low of $28.86 and a twelve month high of $63.20.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.01. The business had revenue of $486.30 million for the quarter, compared to analyst estimates of $440.68 million. Astrana Health had a return on equity of 10.71% and a net margin of 4.30%. Astrana Health’s revenue was up 39.7% compared to the same quarter last year. During the same period last year, the firm posted $0.28 earnings per share. On average, analysts anticipate that Astrana Health will post 1.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Astrana Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC bought a new stake in Astrana Health in the third quarter worth approximately $34,000. Nisa Investment Advisors LLC bought a new stake in Astrana Health in the third quarter worth approximately $35,000. Central Pacific Bank Trust Division bought a new stake in shares of Astrana Health during the third quarter valued at approximately $160,000. Everence Capital Management Inc. bought a new stake in shares of Astrana Health during the third quarter valued at approximately $272,000. Finally, Granite Bay Wealth Management LLC bought a new stake in shares of Astrana Health during the third quarter valued at approximately $290,000. 52.77% of the stock is owned by institutional investors and hedge funds.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.